Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

versus 4% for placebo.

Seizures: In short-term placebo-controlled trials (4- to 6-weeks), seizures occurred in 0.1% (1/1344) of patients treated with Fanapt compared to 0.3% (2/587) on placebo. As with other antipsychotics, Fanapt should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.

Orthostatic Hypotension and Syncope: Fanapt can induce orthostatic hypotension and syncope. Fanapt should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions that predispose the patient to hypotension.

Leukopenia, Neutropenia, and Agranulocytosis: In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents. Agranulocytosis (including fatal cases) have been reported. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue Fanapt at the first sign of a decline in WBC in the absence of other causative factors.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, Fanapt elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia and impotence have been reported in patients receiving prolactin-elevating compounds.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing Fanapt for patients who will be experiencing conditions which may contribute to an elevation in core body temperature.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity an
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Rebiotix Inc. announced this morning that results of ... RBX2660 (microbiota suspension) will be presented in two posters and ... Philadelphia from October 8-12. ... session on Thursday, October 9, 2014: Poster: RBX2660 ... Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... September 17, 2014 According to ... Component (Sensor, Battery, Memory Device, Display, & Microprocessor/MCU), by ... Wellness), and by Geography - Global Forecast to 2020", ... market is expected to reach $56.50 Billion by 2020, ... 2020. Browse 235 market data Tables and ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4
... (Nasdaq: ENDP ) today announced that it will present ... 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president ... programs. The presentation will be webcast live and can ... investors section.   About Endo ...
... nation,s leading retail pharmacy, brings its "To Your Health" ... Texas. The program will provide free preventive health screenings ... through November as a way to help citizens determine ... a path to better health. (Logo: ...
Cached Medicine Technology:CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 2CVS/pharmacy Debuts the 'To Your Health' Program in Dallas and Fort Worth Texas, Bringing More Than 80 Free Health Screening Events to the Community 3
(Date:9/18/2014)... Angeles, CA (September 18, 2014) Cardiovascular disease is ... cholesterol plays a major role in accelerating its ... a treatment to decrease cholesterol-carrying lipoproteins such as ... harmful. A new study, out today in the ... finds that rosuvastatin may be more effective among ...
(Date:9/18/2014)... 2014 On August 23, the ... with the Distinguished Service Award for his contributions to ... 2014 National Basketball Retired Players Association (NBRPA) Legends World ... the Chicago Bulls in 1977, Glenn would go on ... Knicks, the Atlanta Hawks, and the Milwaukee Bucks throughout ...
(Date:9/18/2014)... September 18, 2014 One Week Kitchens will ... the Bloomsburg Fair beginning this Saturday. Their display will be ... great example of the products and design services that are ... various countertops for fair-goers to see. This display won ‘Most ... earlier this year and really is something to see. ...
(Date:9/18/2014)... September 18, 2014 Demand for competency-based ... seek more efficient routes to job placement and employers ... not have come at a better time as the ... supply. , Working in collaboration with employers, career educators ... approach to CBE implementation and direct assessment ...
(Date:9/18/2014)... 2014 SpineFrontier is expanding its ... partners in Less Exposure Surgery Technology by hiring ... an extensive education curriculum and trained sales representatives ... in Organizational Leadership, and has educated and trained ... Bringing her to the team is a big ...
Breaking Medicine News(10 mins):Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 2Health News:The HearStrong Foundation Recognizes Mike “Stinger” Glenn with the Distinguished Service Award at the 2014 Legends World Sports Conference 3Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Wonderlic Unites Employers, Career Educators and Competency-Based Education Experts to Help Narrow Skills Gap 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2
... has come out with a finding published in the journal ... substance like marijuana, alcohol, and cigarettes in solitude, tend to ... to have a harder time quitting, as opposed to those ... ,The results stem from a study spreading over ...
... genome is remarkably similar to that of humans' and may ... //University of Central Florida professor Cristina Calestani and several colleagues ... November issue of Science. ,Sea urchins are ... sea urchin has been used for many years as a ...
... reports success of rapid 3-D cell-growth technique that produces ... lab, it looks, contracts //and responds almost like natural ... goal of creating replacement parts for damaged human hearts, ... a spoonful of loose heart cells. ,This ...
... will do the rounds of rural areas as part of ... marginalized populations. // ,The government has released initial ... to set up mobile medical units in rural areas. ... been given under the National Rural Health Mission (NRHM) scheme ...
... Brain scans may help doctors predict schizophrenia, a mental disorder ... a new study. // ,Researchers at the University of ... a high risk of developing schizophrenia because two or more ... online edition of BBC News said. ,The researchers ...
... scheme 'Assistance for capacity Building', Ministry of Health ... maximum //of Rs. 1.50 crores or actual, whichever ... facilities of State Hospitals of towns/cities located on ... Department of Road Transport and Highways and Ministry ...
Cached Medicine News:Health News:Sea Urchin Genome Similar To Man And May Cure Diseases 2Health News:A New Rapid 3-D Cell-Growth Technique For Growing Heart Muscle 2Health News:A New Rapid 3-D Cell-Growth Technique For Growing Heart Muscle 3
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
Medicine Products: